Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor MK-1775 in Combination With Cisplatin and Radiation in Cervical Cancer
This is a phase 1 study to find the best dose of a new investigational drug MK-1775 as well
as to see how safe the drug is in combination with cisplatin and radiation in patients with
MK-1775 is a new drug which may block Wee1 protein activity. When given in combination with
cisplatin and radiation therapy, MK-1775 may help prevent the Wee1 protein from repairing damaged
tumour cells without causing harm to normal cells. This is believed to increase the
effectiveness of cisplatin and radiation therapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society